

## Instructions for Use

# XonRID®

### Topical gel for radiotherapy induced dermatitis

Xonrid® is a topical gel that prevents and treats skin symptoms such as erythema, itching, burning sensation and pruritus, induced by radiotherapy or other causes.

When applied to the target skin areas, Xonrid® forms a protective film, reduces the TEWL (Trans Epidermal Water Loss) and increases moisturizing.

Xonrid® promotes the healing process by restoring the physiological hydration levels of the affected skin areas.

Xonrid® can be applied to the target areas including skin folds and creases, with or without minor trauma or abrasions.

### Ingredients

AQUA, C12-15 ALKYL-BENZOATE, CHAMOMILLA RECUTITA, GLYCERIL STEARATE, XANTHAN GUM, PROPYLENE GLYCOL, GLYCERIN, PRUNUS AMYGDALUS DULCIS OIL, ETHYLHEXYL PALMITATE, GLUCONOLACTONE, SODIUM BENZOATE, POLYACRYLAMIDE, RASPBERRY KETONE, C13-14 ISOPARAFFIN, DISODIUM EDTA, SODIUM HYALURONATE, TOCOPHERYL ACETATE, LAURETH-7, HYDROLYZED DNA, HYDROLYZED RNA, CAMELIA SINENSIS EXTRACT, VITIS VINIFERA EXTRACT, CALCIUM GLUCONATE.

### Application of the product

To be used on clean skin three times a day or as indicated by the physician.

Apply with clean hands directly to the target areas and gently massage in order to obtain a thin uniform layer.

In case of radiotherapy, you can apply Xonrid® for 2 or 3 days before treatment, after each session and at the end of a cycle as long as needed to obtain relief from symptoms; do not use immediately before the radiation session.

Skin should be perfectly cleaned before each radiation session.

To remove any residual of Xonrid®, gently wash the skin area with clean water before the radiation session.

### **Contra-indications and warnings**

- The use of Xonrid® is contra-indicated in any patient with a known history of hypersensitivity to any of the ingredients
- For external use only; do not use in contact with mucosae, or in contact with eyes
- Do not use in combination with other topical products, as possible interactions are not excluded
- Xonrid® has a barrier effect that could affect the in-situ absorption of topical drugs
- Do not use in presence of severe dermal lesions that can heal only on secondary intent (e.g. severe wounds that have substantially and extensively breached the dermis, chronic extensive ulcerated wounds, severe burns, severe decubitus wounds)
- Dermatitis usually recovers in 2 or 3 weeks after the end of radiotherapy; if symptoms are persistent, discontinue the use of the product and seek medical advice
- Do not use if the dispenser is damaged or tampered, if it has been inappropriately stored, or after expiry date reported on the label.

Xonrid® is a trade mark of Helsinn Healthcare SA

### **KEEP OUT OF THE REACH OF CHILDREN.**

Store at room temperature.

### **Packaging**

Bottle containing 75 ml of Xonrid®.

 **Manufactured by** Helsinn Healthcare SA,  
Via Pian Scairolo 9, 6912 Pazzallo - Lugano - Switzerland



**Currently not distributed in Spain**

**REF** 04B

Last revision: 04/2018

 **HEL SINN**  
*Integrative Care*